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Abstract
Individuals with schizophrenia tend to be heavy smokers and are at high risk for tobacco dependence. However, the nature
of the comorbidity is not entirely clear. We previously reported evidence for association of schizophrenia with SNPs and SNP
haplotypes in a region of chromosome 5q containing the SPEC2, PDZ-GEF2 and ACSL6 genes. In this current study, analysis
of the control subjects of the Molecular Genetics of Schizophrenia (MGS) sample showed similar pattern of association with
number of cigarettes smoked per day (numCIG) for the same region. To further test if this locus is associated with tobacco
smoking as measured by numCIG and FTND, we conducted replication and meta-analysis in 12 independent samples
(n.16,000) for two markers in ACSL6 reported in our previous schizophrenia study. In the meta-analysis of the replication
samples, we found that rs667437 and rs477084 were significantly associated with numCIG (p= 0.00038 and 0.00136
respectively) but not with FTND scores. We then used in vitro and in vivo techniques to test if nicotine exposure influences
the expression of ACSL6 in brain. Primary cortical culture studies showed that chronic (5-day) exposure to nicotine
stimulated ACSL6 mRNA expression. Fourteen days of nicotine administration via osmotic mini pump also increased ACSL6
protein levels in the prefrontal cortex and hippocampus of mice. These increases were suppressed by injection of the
nicotinic receptor antagonist mecamylamine, suggesting that elevated expression of ACSL6 requires nicotinic receptor
activation. These findings suggest that variations in the ACSL6 gene may contribute to the quantity of cigarettes smoked.
The independent associations of this locus with schizophrenia and with numCIG in non-schizophrenic subjects suggest that
this locus may be a common liability to both conditions.
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Introduction
Smoking is an important public health problem, and smoking-
related diseases take a heavy toll on society. Many studies have
shown that smoking is addictive and both genetic and environ-
mental factors influence smoking behaviors. In recent years, with
the application of genome-wide association study (GWAS)
approach, genetic studies of smoking have made significant
progress. One example is the identification of the CHRNA5/
CHRNA3/CHRNB4 locus as a risk factor for smoking quantity [1–
3]. However, this and other established loci explain only a small
proportion of the heritability observed for smoking behaviors.
Many more genes remain to be identified for their effects on
smoking behaviors.
Smoking is highly prevalent among individuals with a variety of
psychiatric disorders [4,5]. Among them, the comorbidity with
schizophrenia is particularly high. Smoking prevalence in those
with a schizophrenia diagnosis is 3–4 times higher than that in the
general population. Most individuals with schizophrenia smoke
more heavily than smokers in the population at large [6]. Several
hypotheses have been proposed to explain these phenomena,
including a self-medication theory [7,8]. It is possible that
schizophrenic patients smoke to enhance cognition and to inhibit
side-effects of neuroleptic drugs, or schizophrenia has an inherited
vulnerability to heavy smoking behavior. In a previous study, we
found evidence that the SPEC2/PDZ-GEF2/ACSL6 locus is
associated with schizophrenia [9]. In the present study, in our
analyses of smoking phenotypes for the control subjects of the
Molecular Genetics of Schizophrenia (MGS) sample, we found
substantial association in the acyl CoA synthetase long chain 6
(ACSL6) gene with a phenotype based on a categorized number of
cigarettes smoked per day (numCIG). To verify if this locus is
associated with numCIG, we initiated replication studies using 12
other independent samples.
It is unknown how ACSL6 variants might affect tobacco smoking
and there are no probes available to assess levels of ACSL6 in the
brains of humans. Because nicotine is a major psychoactive
ingredient in tobacco that is self-administered in both humans and
rodents [10], we used rodent models to determine if chronic
nicotine exposure alters ACSL6 expression in brain areas involved
in addictive behaviors and cognition. We conducted in vitro and in
vivo studies, measuring the effects of chronic nicotine exposure on
ACSL6 mRNA expression in rat primary cortical culture and
assaying levels of ACSL6 protein in mouse prefrontal cortex (PFC),
hippocampus (HIP), ventral tegmental area (VTA) and nucleus
accumbens (NAC) following chronic nicotine exposure in the
presence or absence of a nicotinic receptor antagonist, mecamyl-
amine. In this article, we report our findings from these
experiments.
Results
ACSL6 association with numCIG in the MGS controls
In our analysis of the interval covering the SPEC2, PDZ-GEF2
and ACSL6 genes (about 800 kb), where we reported a long-range
haplotype association with schizophrenia [9], 69 of the 145
markers have a p value#0.05 for numCIG, far in excess of chance
expectations. In contrast, only 11 markers reach nominal
significance for FTND (Figure 1). The lowest p value (861025)
is observed at rs6870930 for numCIG (beta =20.156,
r2 = 0.0096), which is located in the PDZ-GEF2 gene. Of the 24
markers typed in our previous schizophrenia study [9], rs667437
and rs477086 in the ACSL6 gene are amongst the markers with the
lowest p values for numCIG (p=0.0005; see Figure 1 and Table 1).
However, the association with FTND is not significant. For both
markers, the alleles significantly associated with greater number of
daily cigarettes smoked (allele G for rs667437 and allele C for
rs477086) reside on the risk haplotypes associated with schizo-
phrenia in our previous study.
Replication and meta-analyses of rs667437 and rs477086
We first initiated replication of the finding using our VCU
subjects. For rs667437, both numCIG and FTND reach nominal
significance (p=0.0262 and 0.0427); for rs477086, although no
association is found with FTND (p=0.203), the association with
numCIG reaches nominal significance (p=0.0275) (Figure 2A–
2D). Following these results, we extended the replication study to
other samples, and conducted meta-analyses for all replication
samples. Figure 2 shows the results of the meta-analyses. There is
no significant heterogeneity for either phenotype across the
replication samples (numCIG: rs667437, Q=7.938, p=0.719;
rs477086, Q=7.865, p=0.725; FTND: rs667437, Q=9.192,
p=0.513, rs477086, Q=6.052, p=0.811). For both markers,
numCIG results are significant (rs667437, z=23.56, p=3.8
61024; rs477086, z=23.20, p=0.001362). Similar to the results
we observed in our VCU subjects, the results for FTND are not
significant (rs667437, z=21.66, p=0.097; rs477086, z=21.50,
p=0.134).
Nicotine stimulates ACSL6 mRNA expression in rat
cortical culture
To follow up the finding that ACSL6 is associated with the
number of cigarettes smoked, we next questioned if nicotine in
tobacco might affect expression of ACSL6 in the central nervous
system. We used animal models to determine whether nicotine
affects the expression of ACSL6 in comparative rodent brain areas
thought to regulate nicotine/tobacco use and involved in
schizophrenia. We first conducted chronic nicotine stimulation
experiments in primary rat cortical cultures using 10 and 100 mM
nicotine, and measured the mRNA expression of ACSL6 by real-
time quantitative PCR. There is a main effect of nicotine exposure
on mRNA expression of ACSL6 (F2, 6 = 78.844, p,0.001; Figure 3).
A post hoc t-test reveals that on day 5, the mRNA expression in the
nicotine-treated samples is significantly higher than that in the
saline controls independent of the concentration of nicotine
(t8 =23.579, p,0.01). The effects on days between the doses are
marginal (t8 = 2.293, p=0.051 for day 3 and t8 = 2.278, p=0.052
for day 5). These results suggest that nicotine stimulates ACSL6
mRNA expression in cortical cells. Rat GAPDH and TATA box
binding protein (TBP) primers were used as internal controls.
Results from GAPDH and TBP did not differ significantly and
therefore, only TBP data was shown (Figure 3).
Nicotine increases ACSL6 protein levels in mouse
prefrontal cortex (PFC) and hippocampus (HIP)
We further tested whether nicotine alters ACSL6 protein
expression following in vivo nicotine exposure. We chronically
administrated a dosing regimen of 36 mg/kg/day nicotine via
mini-pumps for 14 days that has been shown to result in
dependence-like behavior in mice [11,12]. On day 15, mice
received a challenge s.c. injection of 1 mg/kg mecamylamine or
saline vehicle 30 min prior to brain harvest. Four brain areas
(PFC, HIP, NAC and VTA) were dissected and processed for
Western blotting to quantify the expression levels of ACSL6
protein. The results are shown in Figure 4. There is a significant
interaction of nicotine pretreatment with mecamylamine challenge
in the PFC (Figure 4A, F1,11 = 16.420, p=0.004) and HIP
ACSL6 and numCIG
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(Figure 4B, F1,27 = 8.290, p=0.008), but not in the NAC
(Figure 4C) and VTA (Figure 4D) after chronic nicotine treatment.
Post hoc t-tests reveal that animals receiving chronic nicotine show a
significant increase in ACSL6 protein expression in the PFC
(t4 = 4.872, p=0.008) and HIP (t16 = 4.583, p,0.001) of NIC-SAL
compared to SAL-SAL control animals. This was not observed
following a withdrawal-precipitating dose of the non-selective
nicotinic antagonist, mecamylamine. Mecamylamine treatment
alone does not change the expression of ACSL6 protein in the
brain regions tested (F’s,1.0 in SAL-SAL compared to SAL-MEC
mice), but does reverse nicotine associated increases in ACSL6.
Mice receiving an injection of mecamylamine following 14 days of
chronic nicotine treatment (NIC-MEC) produce significantly less
ACSL6 protein than saline-injected controls (NIC-SAL) in both the
PFC (t4 = 5.38, p=0.006) and HIP (t12 = 3.221, p=0.007).
Together these data suggest that continued activation of nicotinic
acetylcholine receptors is necessary for the increases of ACSL6
protein in these brain regions.
Discussion
In our analyses of the numCIG and FTND phenotypes in the
MGS control subjects, we found that multiple markers in the
broad region containing the SPEC2, PDZ-GEF2 and ACSL6 genes
showed substantial association with number of cigarettes smoked.
While the association signals in these genes did not reach genome-
wide significance, the wide spread association signals in the region
are consistent with the patterns we observed in our previous
schizophrenia studies. Given the high rate of smoking in
schizophrenic patients, we sought to test whether this locus is
independently associated with tobacco smoking as measured by
numCIG and FTND scores in non-schizophrenic subjects. Of the
Table 1. ACSL6 association with numCIG and FTND in the MGS_EA sample.
numCIG FTND
SNP Effect allele BETA SE STAT P BETA SE STAT P
rs667437 A 20.1351 0.03881 23.492 0.0005 20.1897 0.1219 21.557 0.1197
rs477086 T 20.1351 0.03883 23.491 0.0005 20.1829 0.1219 21.501 0.1337
doi:10.1371/journal.pone.0028790.t001
Figure 1. Association analyses of the MGS_EA controls for the SPEC2, PDZ-GEF2, FNIP1 and ACSL6 region. Of the 145 markers tested in
this interval, 68 and 12 markers respectively reached nominal significance for numCIG and FTND. The two markers selected for replication were
highlighted as red.
doi:10.1371/journal.pone.0028790.g001
ACSL6 and numCIG
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many markers typed in this region in the MGS control sample, we
found two overlap markers in our previous study [9], rs667437
and rs477086. The association signals for numCIG from these two
markers are among the most significant SNPs identified and are
representative of the region. Therefore, we initiated replication of
these two ACSL6 markers in a large population twin sample
selected from our twin studies (VCU subjects). In our VCU
subjects, both markers, rs667437 and rs477086, reached nominal
significance and the risk alleles are the same as those observed in
the MGS control subjects. Encouraged by these results, we
recruited participation by investigators with independent samples.
Using standard meta-analyses, we demonstrate that both markers
are significantly associated with the numCIG phenotype and the
FTND phenotype shows a trend in the same direction. As these
studies were performed with non-schizophrenic subjects, the
associations observed are independent of schizophrenia diagnosis.
The observation that the same alleles in ACSL6 are associated with
schizophrenia and with numCIG in non-schizophrenic subjects
raises an interesting question as to whether there is a common
mechanism underlying these associations. To answer this question,
we need a sample with both schizophrenia and cigarettes smoking
phenotypes. With such a sample, we could estimate how much of
the association with schizophrenia can be accounted for by
cigarette smoking, and evaluate the relationship between these two
separate associations.
ACSL6 encodes a key enzyme that activates polyunsaturated
long chain fatty acids and is involved in lipid metabolism. Its
preferred substrates include arachidonic acid, eicosapentaenoic
acid and docosahexaenoic acid [13]. Arachidonic acid is a
component of arachidonoyl phosphatidyl choline and arachidonic
acid-containing inositol phospholipids, which are the major
sources of N-arachidonoyl ethanolamine (anandamide) and 2-
arachidonoylglycerol (2-AG) [14]. Anandamide and 2-AG are the
major endocannabinoids that bind to the cannabinoid receptor 1,
a receptor associated with tobacco smoking and other addictive
drugs in humans [15–18] and shown to promote nicotine reward
in animal model studies [19–21]. We have reported that the
cannabinoid receptor 1 target is associated with tobacco smoking
and nicotine dependence [18]. Others have provided evidence
that the endogenous cannabinoid system plays a major role in
drug reward and addiction, including nicotine [22–28]. Intrigu-
ingly, it has been proposed that the endocannabinoid system is
involved in the etiology of schizophrenia [29] and cannabis use is
considered a risk factor for schizophrenia as well [30]. While the
exact role of ACSL6 in schizophrenia and tobacco addiction is
unclear at this time, these data warrant further investigation into
the potential interactions of ACSL6 and the cannibinoid system.
Since nicotine is the major psychoactive ingredient in tobacco
and ACSL6 genotype was associated with number of cigarettes
smoked, we sought to characterize if nicotine affects expression of
Figure 2. Meta-analyses of rs667437 and rs477086 for numCIG and FTND. A) rs667437, numCIG; B) rs477086, numCIG; C) rs667437, FTND;
and D) rs477086, FTND.
doi:10.1371/journal.pone.0028790.g002
ACSL6 and numCIG
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ACSL6 in brain areas that regulate cognition, attention, and
addiction behaviors. Using primary cell culture of rat cortex, we
show that nicotine stimulates ACSL6 mRNA expression after 5
days but not 3 days of nicotine exposure. These data suggest that
repeated nicotine exposure is necessary for nicotine-associated
changes in ACSL6. In rodents, humans and non-human primates,
the cortex is thought to regulate executive functions that support
working memory, cognition and inhibitory control [31–34]. The
PFC communicates with the HIP which is important for
declarative memory and integration of higher brain signals with
information projected from sensory systems. This circuitry is
compromised in those with schizophrenia who are thought to
smoke in part to enhance cognition [33]. Utilizing a mouse model
of nicotine exposure that we have previously shown to produce
nicotine dependence-like behavior as measured by tolerance and
withdrawal [11,35], we find that chronic systemic exposure to
nicotine increases ACSL6 protein levels in the PFC and HIP of
mice. It is interesting that nicotine does not affect the expression of
ACSL6 in the VTA and NAC, areas of the brain that regulate
addiction and reward behavior [36–38], but the PFC and HIP that
have inputs to the VTA and NAC and are also thought to
contribute to tobacco addiction [39–43]. Interestingly, the ACSL6
gene appeared in the list of amphetamine addiction genes by an
independent GWAS [44], suggesting that ACSL6 may be involved
in addictive behaviors to drugs other than nicotine. The
observation that nicotine-associated increases in ACSL6 are
inhibited by the nicotinic receptor antagonist mecamylamine
suggests that sustained increases of ACSL6 protein require
activation of nicotinic receptors. It is not clear if this effect is
due to changes in transcription or protein degradation and since
mecamylamine blocks all nicotinic receptors in brain, further
studies should question which receptor subtypes mediate these
effects. Although the mechanism of these findings has yet to be
determined, our finding is consistent with several studies that have
implicated nicotinic receptors in the etiology of schizophrenia [45–
47] and the quantity of daily cigarettes smoked [1–3,48].
It is not clear whether nicotine-associated increases in ACSL6
expression might serve to improve cognition and/or enhance
neuroplasticity associated with nicotine dependence in individuals
with schizophrenia. Many studies have shown that smoking can
improve cognitive function, memory and attention in both normal
controls and schizophrenia patients [49–52] and the effects of
cannabinoids on cognitive function and memory [53,54] are
thought to be mediated in part by the cholinergic system [55,56].
These findings also warrant future studies to determine if
alterations of ACSL6 in brain might support self-medication,
cigarette craving, withdrawal or primary or conditioned reinforc-
ing effects of cigarettes.
In our previous fine-mapping study of schizophrenia, we found
that haplotypes spanning SPEC2, PDZ-GEF2 and ACSL6 genes
were associated with the disease [9]. In the current study, we found
that this same genomic interval showed a similar pattern of
association with numCIG in the MGS controls, an association that
we confirmed in a meta-analysis of 12 independent samples of
non-schizophrenic subjects. Since the ACSL6 gene is in high LD
with other genes, i.e. SPEC2 and PDZ-GEF2, we cannot exclude
the possibility that the observed association signals may reflect the
activity of other genes in this region, but our rodent studies suggest
that nicotine in tobacco increases expression of ACSL6 message
and protein. Given the heavy tobacco use of individuals diagnosed
with schizophrenia, our results raise interesting questions in regard
to whether schizophrenic smokers may ingest tobacco to regulate
ACSL6. In separate studies, several other genes have been
associated with both nicotine dependence [18,20,57] and
schizophrenia [58–64]. The SPEC2, PDZ-GEF2 and ACSL6 region
may be another locus that contributes to shared susceptibility to
schizophrenia and tobacco addiction. Taken together, these
studies provide convergent evidence that tobacco use and
schizophrenia may share some common underlying mechanisms
and that common vulnerability genes such as ACSL6 are regulated
by nicotinic receptors.
Materials and Methods
Human studies
This study was conducted according to the principles expressed
in the Declaration of Helsinki. For all human studies, all
participants provided written informed consent. The study
protocol, forms, and procedures were approved by Institutional
Review Boards/Ethics Committees at Virginia Commonwealth
University (VCU subjects), Yale University School of Medicine
(The Yale/UConn subjects), University of Virginia (MSTF study)
and all the other participating Institutional Review Boards.
MGS controls. The control subjects for the MGS were a
population sample selected for the GWAS of schizophrenia [65].
Subjects were sampled proportionally from 25 major population
areas. All subjects completed an online, short, self-report clinical
assessment after giving informed consent through an online
procedure and prior to venipuncture being arranged. The self-
report screen focused on common psychiatric disorders including
substance use problems, along with age, sex, height, weight, and
the ethnic background of their grandparents. Specific to smoking
phenotypes, the subjects were ascertained with the full FTND
questionnaire. The information corresponding to the FTND was
extracted from the phenotype dataset. FTND scores were obtained
based on the answers of the participants to the questionnaires.
Subjects who did not smoke a whole cigarette (a ‘‘No’’ answer to
the question, ‘‘Have you ever smoked a whole cigarette?’’) were
excluded from FTND score calculation. To be consistent with
ascertainment of our VCU subjects, only subjects who answered
Figure 3. ACSL6mRNA expression in rat cortical primary culture
after nicotine treatment. The expression levels of ACSL6 mRNA were
significantly increased by 5 days of nicotine exposure for both doses.
*p,0.01 compared to saline controls; n = 3. mRNAs were measured by
real-time-PCR, and were presented as normalized DCt values. Bars
represent 6 SD.
doi:10.1371/journal.pone.0028790.g003
ACSL6 and numCIG
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‘‘Yes’’ to the question ‘‘did you smoke cigarettes on a daily basis’’
and who smoked $5 cigarettes per day were included in the
analyses of FTND. The numCIG phenotype was constructed
using the raw number of cigarettes smoked per day at the time
when the subjects smoked most heavily in their lifetime. Based on
the raw data distribution, we divided the subjects into 4 categories
using these cut-offs: 0 for those who smoked 1 cigarette per day; 1
for those who smoked 2–14 cigarettes per day; 2 for those who
smoked 15–25 cigarettes per day and 3 for those who smoked 26
cigarettes per day or more. For the numCIG phenotype, all
subjects reporting smoking were included in the analyses. The
MGS controls included both European Americans (MGS_EA) and
African Americans (MGS_AA). For this study, there were 1,342
and 1,843 European American (EA) subjects having FTND and
numCIG phenotypes respectively, and 454 and 639 AA subjects
having FTND and numCIG phenotypes, respectively. The
distributions of these phenotypes are shown in Figure S1. The
distribution of both phenotypes is normal.
The SAGE subjects. The Study of Addiction: Gene and
Environment (SAGE) is part of the Gene Environment Association
Studies initiative (GENEVA) funded by the National Human
Genome Research Institute aiming at understanding the impact of
genes and environments on substance dependence and addiction.
The SAGE sample consisted of 3 subsamples: the Collaborative
Study on the Genetics of Alcoholism (COGA) [66], the Family
Study of Cocaine Dependence (FSCD) [67], and the Collaborative
Genetic Study of Nicotine Dependence (COGEND) [1]. Although
FTND scores were available for all subjects, the raw number of
cigarettes smoked per day was not available. Instead, subjects were
assigned to one of the four categories based on the FTND
questionnaire that grouped individuals by the number of cigarettes
smoked per day (subjects were assigned 0 if they smoked 0–10
cigarettes; 1 if they smoked 11–20 cigarettes; 2 if they smoked 21–
30 cigarettes and 3 if they smoked more than 30 cigarettes per
day). The SAGE sample included 2,125 subjects with self-reported
European ancestry (SAGE_EA) and 904 subjects with self-
reported African ancestry. For the FSCD subsample, only one
subject from each family was used.
The Lung cancer and smoking study. This is a GWAS to
investigate the genetic determinants of lung cancer risk. This study
is also part of the GENEVA initiative and consisted of two
samples. The first is the Environment and Genetics in Lung
Cancer Etiology Study (EAGLE) [68], a population-based,
biologically intensive, case-control study from the Lombardy
region of Italy including ,2,000 newly diagnosed lung cancer
cases and ,2,000 age-, gender- and region- matched controls.
Figure 4. Western blot analyses of ACSL6 protein in mouse brain regions after chronic nicotine exposure and mecamylamine
challenge. Nicotine (NIC+SAL) led to a significant increase in ACSL6 protein levels in A) the prefrontal cortex and B) the hippocampus [*p,0.01
compared to saline controls (SAL+SAL)]. These increases were suppressed by the administration of mecamylamine (NIC+MEC;# p,0.01 compared to
nicotine treated NIC-SAL mice). There was no effect of nicotine on levels of ACSL6 in C) the NAC and D) VTA. (n sizes = 3–8 per group).
doi:10.1371/journal.pone.0028790.g004
ACSL6 and numCIG
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This study is also referred to as the Smoking and Lung Disease
(SLD) study. The second is the Prostate, Lung, Colon and Ovary
(PLCO) [69,70] Cancer Screening Trial, from which ,850 lung
cancer cases and ,850 controls matched on age and gender were
used. The subjects were ascertained for a variety of smoking
phenotypes, including smoking status, persistent smoking, quit
attempts, and the Fagerstro¨m questionnaire. PLCO participants
were all EA and EAGLE included subjects from Italy who were all
with European ancestry. EAGLE is a case-control study and
includes 3,937 phenotyped subjects. PLCO is a screening trial with
a cohort design and includes 1,651 phenotyped subjects.
The VCU subjects. The subjects from the Virginia
Commonwealth University were selected from the Mid-Atlantic
Twin Registry. In this study, we selected regular smokers (defined
as those who smoked at least 7 cigarettes per week for a month or
more) from our population twin studies [71–73]. Tobacco smoking
and nicotine dependence were assessed by the Fagerstro¨m
Tolerance Questionnaire (FTQ) and/or FTND [74,75]. All
regular smokers with DNA samples were included except when
self-reported ancestry was not Caucasian. One of the co-twins was
selected randomly for inclusion. The final sample included 2,138
individuals, with 1,438 males and 700 females. All subjects were
aged 18 to 65 at the time of FTND ascertainment and all self-
reported being of European ancestry.
Mid-South Tobacco Family (MSTF) study. The subjects of
the MSTF study with either AA or EA origin were recruited
primarily during 1,999–2,004 from the Mid-South states of
Tennessee, Mississippi, and Arkansas. Proband smokers were
required to be at least 21 years old, to have smoked for at least 5
years, and to have consumed at least 20 cigarettes per day for the
last 12 months. Siblings and biological parents of a proband
smoker were recruited whenever possible, regardless of their
smoking status. The study includes 2,037 participants in 602
nuclear families, with 671 subjects in 200 EA families and 1,366
subjects in 402 AA families. The degree of nicotine dependence of
each smoker was ascertained by the three most commonly used
measures: Smoking Quantity (SQ; defined as the number of
cigarettes smoked per day), the Heaviness of Smoking Index (HSI;
0–6 scale), and the FTND score (0–10 scale). All three measures
have been used consistently in previous reports on nicotine
dependence in this sample [57,76–78]. In this study, only the
FTND scores and numCIG phenotypes were used.
The Yale/UConn subjects. The subjects involved in the
Yale/UConn study were both families and unrelated individuals.
The family samples were recruited from several clinical sites
(principally from Yale University School of Medicine and the
University of Connecticut Health Center, but also from McLean
Hospital and the Medical University of South Carolina) through
siblings meeting DSM-IV criteria for cocaine dependence or
opioid dependence. The sample of unrelated individuals was
ascertained as cases affected for cocaine, opioids, or alcohol
dependence and screened controls. The Yale/UConn family
sample included 2,129 AAs (including 132 self-reported Hispanics)
and 1,706 EAs (including 310 self-reported Hispanics) [79]. Of
these, 1,858 subjects from 893 families had genotype and
phenotype data. The Yale/UConn case control sample included
1,912 AAs (including 76 Hispanics) and 1,476 EAs (including 176
Hispanics).
Marker Selection, genotyping and genotype
imputation. Since our initial goal was to test whether markers
associated with schizophrenia were also associated with smoking
and nicotine dependence phenotypes, we compared the markers
from our schizophrenia study with those included in the
Affymetrix 6.0 chipset (the MGS samples were first genotyped
with this chipset) in the PDZ-GEF2/ACSL6 region. We found that
only 2 of the markers (rs667437 and rs477086) used in our
previous schizophrenia study were in the 6.0 chipset. Although the
association of these two markers with schizophrenia was not
among the strongest observed in the schizophrenia study, they
were among the best results in our initial association analyses of
the MGS sample. Therefore, only these 2 markers were selected
for the present study.
For the GWAS datasets (MGS, SAGE and Lung Cancer), DNA
preparation and genotyping have been reported previously. The
MGS subjects were typed using an Affymetrix platform (SNP 6.0),
and the SAGE and Lung Cancer subjects were typed using an
Illumina platform (Human 1 M-Duo). For these datasets, we
accepted the quality filtering procedures of each individual study
and used the genotypes directly after download. The VCU
subjects, the Yale/UConn and MSTF subjects were genotyped by
each group using the TaqMan method. For the 2 SNPs used in
this study, the assays were designed and synthesized by Applied
BioSystems (Foster city, CA, USA). Standardized procedures
recommended by the manufacturer were used. The Illumina
marker set included only one of the two SNPs used in this study:
rs477086. The genotypes for rs667437 were imputed using the
fastPHASE program [80] with the MGS_EA or MGS_AA as a
reference panel for the EA and AA samples respectively.
Imputations were also conducted with HapMap subjects as
references, and the imputed genotypes were almost identical to
those using MGS samples as references.
Association and meta-analysis. Association analyses were
performed for each sample with the PLINK software package
[81]. We used two phenotypes, FTND score and numCIG, where
numCIG was a categorical phenotype. Both phenotypes were
treated as quantitative traits in linear regression. For population
samples, we used linear regression with sex, age and ethnicity
(Hispanics) as covariates. For family samples, we used the QFAM
module and the within-family statistics (MSTF, Yale_EA_Fam
and Yale_AA_Fam samples). For GWAS datasets, we adapted the
principle components used in the original studies. Meta-analyses
were performed with the GWAMA software package [82] for
replication samples only. Summary statistics (beta, se and sample
size) were extracted from individual analyses and used in the meta-
analyses. The package can perform both fixed effect and random
effect meta-analyses. In our analyses, since the heterogeneity tests
(both Cochran’s Q statistics and I2) were non-significant, we
reported the results from the fixed effect analyses. Meta-analysis
results were plotted with the R package rmeta.
Animal studies
The experimental protocol was approved by the Institutional
Animal Care and Use Committee at Virginia Commonwealth
University (the University Animal Welfare Assurance Number:
A3281-01), and all animals were treated according to the Guidelines
for the Care and Use of Laboratory Animals, as set forth by the National
Institutes of Health. Animals were maintained on a 12-hour light/
dark cycle in a temperature (21uC) and humidity controlled
vivarium with ad libitum access to food and water. Experiments
were performed during the light cycle.
Rat in vitro expression study. Sprague–Dawley timed-
pregnant rats were obtained from Zivic Laboratories (Allison
Park, PA, USA). On postnatal day 1, the litter was transferred
together to the laboratory where brain harvests took place.
Mixed neuronal plus glial cultures were prepared as described
previously [83,84]. Briefly, the cortex of 4–5 pups was dissected in
a sterile saline solution (137 mM NaCl, 5.3 mM KCl, 0.17 mM
Na2HPO4N7H2O, 0.22 mM KH2PO4 and 0.0012 g/L Phenol
ACSL6 and numCIG
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Red) under a laminar flow hood then transferred into a sterile-
filtered 0.1% porcine trypsin dissection solution, minced and
incubated at room temperature for 10 min. Brain sections were
rinsed twice in plating medium (DMEM, 10% FBS, 1% L-
glutamine and 1% Penicillin/Streptomycin) to stop the trypsin
reaction, triterated with a cotton-plugged glass pipette, spun 7 min
at 1,000 RPM with medium replaced and then poured through a
70 mm nylon cell filter (BD Falcoln, Bedford, MA, USA) for
plating. 1.76106 cells were seeded into each well of a 6-well plate.
Cells were cultured in a 5% CO2 incubator at 37uC. Three days
after plating, and every 3 days thereafter, 1 mL medium was
removed from each well and replaced with 1 mL of fresh mixed
growth medium containing minimal essential medium, 10 mM
glucose, penicillin 100 U/mL, streptomycin 100 mg/mL, and 5%
horse serum. On day 14, in vitro media was removed and 2.0 mL
media was quickly replaced to ensure a consistent stimulating
volume. Cells treated with 0 mM, 10 mM, and 100 mM Nicotine ((-
)-Nicotine hydrogen tartrate salt, dissolved in 0.9% sodium
chloride) were cultured for another 3 and 5 days. At each time
point, the media was removed, wells were washed twice with PBS,
and cells were harvested in 200 ml PBS. Cells from three wells
were pooled into an Eppendorf tube. Total RNA was extracted
from cells using TRIzol Reagent (Invitrogen, Eugene, OR, USA)
and quantified by Quant-iTTM RNA Assay Kit (Invitrogen,
Eugene, OR, USA). cDNA was synthesized using 2 mg of total
RNA and 50 ng of random hexamers according to the first-strand
cDNA synthesis protocol provided with SuperScript III RNase H-
Reverse Transcriptase (Invitrogen, Eugene, OR, USA). For real
time-PCR, samples were analyzed in triplicate 20 ml reactions
including 25 ng of cDNA, 250 nmol of primer, 16 PCR buffer,
2 mM MgCl2, 0.08 mM dNTPs, 0.01 u/ml Taq polymerase
(Invitrogen, Eugene, OR, USA) and 1/10 X SyBRH Green
(Sigma, St. Louis, MO, USA). Primers were designed to coding
sequence using Primer3 (v. 0.4.0). PCR reactions using rat TATA
box binding protein (TBP) and GAPDH primers were used as
internal controls. The Primer sequences for the ACSL6, TBP and
GAPDH are as follows: ACSL6 forward, 59-TTTCACGA-
GCGGTACAACAG-39, ACSL6 reverse, 59-GTGTACATCC-
GCACAAGTGG -39; TBP forward, 59-TATAATCCCAA-
GCGGTTTGC-39, TBP reverse, 59-CAGCCTTATGGGGAAC-
TTCA-39; GAPDH forward, 59-AAGGGCTCATGACCACA-
GTC-39, GAPDH reverse, 59-CAACGGATACATTGGGG-
GTA-39. PCR was conducted and the expression level of each
reaction was determined by the CT value. The results from three
replicated assays were averaged to produce a single mean CT value
for each treatment condition. The relative expression level
between ACSL6 and TBP or GAPDH for each condition was
calculated by the 22DCTmethod, whereDCT=CT
ACSL62CT
TBPor GAPDH
[85].
Mouse in vivo expression study. Male 129SvJ mice were
purchased from Jackson Laboratories (Bar Harbor, ME). Animals
were 8–10 weeks of age at the start of the studies. Mice were
anesthetized with sodium pentobarbital (45 mg/kg by
intraperitoneal injection) and implanted subcutaneously (s.c.)
with Alzet osmotic mini pumps [model 2,004, Durect
Corporation, Cupertino, CA, USA] filled with (-)-nicotine (NIC)
or saline (SAL) solution as described in Jackson et al. [11]. The
concentration of nicotine was adjusted according to animal weight
and mini pump flow rate so that mice were infused with 36 mg/
kg/day for 14 days. The dose and duration of nicotine exposure
were chosen based on previous behavioral studies [11,12] which
show that significant tolerance and nicotine withdrawal signs are
produced in mice after this treatment regimen. On the morning of
Day 15, chronic nicotine- and saline-infused mice were injected
s.c. with 1.0 or 2.0 mg/kg of a non-selective nicotinic receptor
antagonist, mecamylamine (MEC) or saline vehicle (SAL) followed
by a 30 min waiting period. There was no significant difference in
ACSL6 protein levels between the 1 and 2 mg/kg doses of
mecamylamine used across cohorts of animals, so these data were
combined to create 4 experimental treatment groups (SAL+SAL,
SAL+MEC, NIC+SAL, NIC+MEC). Mice were then euthanized
by cervical dislocation. Brain sections were dissected and placed
immediately in cold extraction buffer for dissection of PFC, HIP,
NAC and VTA. Brain tissues were dissected and homogenized as
described previously [86]. Protein concentrations were determined
using the DC protein assay (Bio-Rad Laboratories, Hercules, CA,
USA), and 30 mg of protein were mixed with 66blue gel loading
dye (New England Biolabs, Ipswich, MA, USA) and heated for
5 minutes at 95uC. Samples were then separated by SDS-
polyacrylamide gel electrophoresis on a 10% Tris-HCL gel and
subjected to immunoblotting with anti-ACSL6 antibody (1:500
from goat; sc-48005, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) or anti-GAPDH (1:50,000 from mouse; Advanced
ImmunoChemical Ins., Long Beach, CA, USA) primary
antibodies overnight at 4uC. Blots were rinsed in TBST and
then incubated in secondary antibodies (1:2000 anti-goat or
1:50,000 mouse, Vector Laboratories, Inc., Burlingame, CA,
USA) for 1 hour at room temperature followed by three times of
TBST 10 min washes. Specific bands were detected by enhanced
chemiluminesence (GE Healthcare Bio-Sciences, Piscataway, NJ,
USA), exposed to X-Ray film, and quantified using Image J
software (Rasband WS, National Institutes of Health, Bethesda,
MD; http://rsb.info.nih.gov/ij/, 1997–2006). ACSL6 protein
levels were normalized against GAPDH for loading control and
against vehicle-treated control subjects to enable comparisons
across blots.
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